Companies › Gritgen Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Hematology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GS1191-0445 injection AAV8-delivered gene therapy expressing B-domain deleted human factor VIII (FVIII) | F8 | Phase 3 | Hemophilia A; Severe Hemophilia A | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06833983 | GS1191-0445 injection | Phase 3 | Hemophilia A | Hematology | Nov 2026 |
| NCT07548411 | GS1191-0445 injection | Phase 1 | Severe Hemophilia A | Hematology | Dec 2029 |
Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Forma Therapeutics Wuhan Createrna Science and Technology Pharmanutra
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.